Skip to main content

Table 1 Characteristics of included studies

From: Self-administered subcutaneous medroxyprogesterone acetate for improving contraceptive outcomes: a systematic review and meta-analysis

Study ID (Trial registration) Study design Number randomized Age of included women Trial arms Duration of treatment (months) Outcomes reported Country
Burke 2018 NCT02293694 Open-label, parallel group, randomized clinical trial 731 18–40 Participants were randomized in a 1:1 ratio to self- or clinician administered subcutaneously DMPA 104 mg 12 Continuation, satisfaction, failure (unintended pregnancy), side effects Malawi
Kohn 2018 NCT02509767 Multicenter, open label, randomized parallel group clinical trial 401 15–44 Participants were randomized in a 1:1 ratio to self- or clinician administered subcutaneously DMPA 104 mg 12 Continuation, satisfaction, failure (unintended pregnancy), side effects USA
Beasley 2014 NCT01019369 Open label, parallel group, randomized clinical trial 132 18 or greater Participants were randomized in a 2:1 ratio to self- or clinician administered subcutaneously DMPA 104 mg 12 Continuation, satisfaction, side effects USA